tm logo
LENTINEXT
Live/Registered
REGISTERED

on 24 Sep 2024

Last Applicant/ Owned by

Nam-gu, Pohang-si Gyeongsangbuk-do

KR

Serial Number

79376166 filed on 22nd Jun 2023

Registration Number

7510377 registered on 24th Sep 2024

in the Principal Register

Correspondent Address

Jong Park

Jong Park The PL Law Group, PLLC

Herndon, VA 20171

United States

Filing Basis

1. filing basis filed as 66 a

Disclaimer

NO DATA

LENTINEXT

Gene transfer agents for preventing and treating human vector-borne diseases; biological preparations, namely, biological vectors for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); biolog Read More

Classification Information


Class [005]
Pharmaceutical Products


Gene transfer agents for preventing and treating human vector-borne diseases; biological preparations, namely, biological vectors for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); biological preparations, namely, biological recombinant vectors for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); biological preparations for gene recombination for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); nucleic acids for medical, medicinal or veterinary purposes; biopharmaceuticals for the treatment of auto-immune diseases; biopharmaceuticals for the treatment of cancer; diagnostic biomarker reagents for medical purposes; reagents for use in medical genetic testing; pharmaceutical preparations for gene therapy and diagnosis of auto-immune diseases and cancer; pharmaceutical preparations for the diagnosis and the treatment of auto-immune diseases; anti-cancer preparations; antibiotics; anti-viral agents; anti-infectives; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cancer cells; cells for medical purposes


First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details


Serial Number

No 79376166

Mark Type

No Service/Collective Mark

Attorney Docket Number

No T59724JD08

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

Yes

66A Current

Yes

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
24th Dec 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24th Sep 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
24th Sep 2024REGISTERED-PRINCIPAL REGISTER
09th Jul 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09th Jul 2024PUBLISHED FOR OPPOSITION
19th Jun 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30th May 2024EXAMINER'S AMENDMENT ENTERED
30th May 2024EXAMINERS AMENDMENT -WRITTEN
30th May 2024EXAMINERS AMENDMENT E-MAILED
30th May 2024APPROVED FOR PUB - PRINCIPAL REGISTER